Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety, tolerability, and effectiveness of Imzokitug combined with Pumitamig and Platinum-Doublet Chemotherapy PDCT compared to Pumitamig and PDCT alone as first-line treatment for adults with locally advanced or metastatic Non-Small Cell Lung Cancer NSCLC. This Phase 2, randomized, open-label study is sponsored by Bristol-Myers Squibb and focuses on patients with stage IV or recurrent unresectable NSCLC. Participants are randomly assigned to one of several treatment groups receiving combinations of Pumitamig, Imzokitug, and histology-based PDCT drugs such as Pemetrexed, Cisplatin, Carboplatin, or Paclitaxel. Each drug is given in specified doses on designated days. The study compares the combination therapies over the treatment period to assess their impact on the cancer. During the trial, participants undergo assessments including tumor measurements using the RECIST v1.1 criteria to determine objective response rate and progression-free survival, along with monitoring for adverse events up to 90 days after treatment ends. The study also tracks overall survival, duration of response, and time to recurrence for up to about four years. Participants will be regularly evaluated by investigators throughout the study duration, which extends to the study completion date in 2030.
Actively Recruiting
Researchers are conducting a combined phase 2b and phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effects on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This multicenter, randomized, double-blind, placebo-controlled trial is designed to provide detailed information on the drugs impact and risks. The study is divided into two parts. Part 1 phase 2b focuses on identifying the optimal dose of CSL300 compared to a placebo over 12 weeks. Part 2 phase 3 assesses the efficacy and safety of CSL300 versus placebo on cardiovascular events such as cardiovascular death or heart attack over approximately 5 years. Participants receive intravenous doses of CSL300 or placebo. The placebo matches the CSL300 product minus the active ingredient. Participants will be monitored through regular assessments including blood tests to measure markers of inflammation like high-sensitivity C-reactive protein hs-CRP, other blood components, and drug levels. The trial tracks cardiovascular events and safety outcomes over the study period. The research team will also observe changes in several blood markers related to inflammation and cardiovascular health. The total follow-up may last up to about five years to fully capture long-term effects and safety.
Actively Recruiting
Researchers are investigating Prodromal Parkinsons Disease by studying the progression of 18F AV-133 PET imaging in participants who show early signs of Parkinsons but have not yet developed typical symptoms. This observational study is part of the Parkinsons Progression Marker Initiative PPMI, aiming to identify biomarkers that signal disease progression and help improve future treatments. The study is international and multi-center, with participants followed for up to 24 months to better understand the disease course during this early stage. Participants will undergo three 18F AV-133 PET imaging scans targeting the vesicular monoamine transporter at the beginning of the study, at 12 months, and at 24 months. Approximately 100 prodromal Parkinsons participants enrolled in the PPMI Clinical 002 study will receive these imaging procedures at up to 10 sites. The study focuses on monitoring changes over time through this specialized imaging technique. During the study, participants will have comprehensive assessments including motor, neuropsychiatric, cognitive, imaging, and biomarker evaluations based on the PPMI Clinical protocol. Researchers will measure the mean rate of change and variability in 18F AV-133 imaging over 24 months, along with clinical motor and cognitive progression and correlations with other clinical and imaging outcomes. Safety will also be monitored by tracking treatment-emergent adverse events throughout the 24-month follow-up period.
Actively Recruiting
Healthy Volunteer
Researchers are conducting the Parkinsons Progression Marker Initiative PPMI, a large, multi-center, observational study to track the progression of Parkinsons disease PD over time. This study includes participants with diagnosed PD, those at risk prodromal PD, and healthy controls. It aims to identify markers related to PD progression by collecting clinical, digital, imaging, biological, and genetic data, which could help in developing therapies to slow PD disability progression. PPMI Clinical plans to enroll up to 4,500 participants who will be followed for 5 to 8 years. Participants may also be invited to join additional related programs such as PPMI Remote, PPMI Digital App, or PPMI Online, depending on their recruitment method and cohort classification. The study collects a wide range of data including clinical assessments, digital outcomes, imaging scans, biological samples, and genetic testing. Participants may undergo repeated evaluations, including imaging tests like SPECT, and provide information through questionnaires and digital tools. Throughout the study, participants will attend visits at regular intervals to undergo assessments that help researchers measure disease progression and compare changes over time. Data collected includes clinical signs, imaging results, biological markers, and genetic information. The study also monitors the probability of disease development in at-risk individuals. The overall duration of participation can extend up to 13 years, ensuring comprehensive long-term data collection and safety monitoring.